Main Article Content


Introduction: Systemic Sclerosis (SSc) is a chronic autoimmune disease, characterized by vasculopathy, specific autoimmune, and fibrosis. Assesment of skin fibrosis by modified Rodnan Skin Score (mRSS) can not detect the minimal changes of skin fibrosis within less
than 3 months. A biomarker is needed to assess the minimal changes of skin fibrosis progressivity with a more objective, quantitative, and rapid way. Procollagen type-1 N-Terminal Propeptide (P1NP), a degradation product of collagen type-1, may become a potential biomarker for skin fibrosis. This study aims to evaluate the correlation between skin fibrosis by mRSS with P1NP serum in systemic sclerosis.

Methods: This was a cross-sectional study performed among systemic sclerosis patients at Rheumatology outpatient clinic, Dr.Hasan Sadikin Hospital Bandung, from May 2016 to July 2016. Skin fibrosis was measured by mRSS. P1NP level was determined by ELISA. Data were analyzed using Rank-Spearman Correlation.

Result: There were thirty-seven subjects, with mean age 37 (SD ±7) years old. Most of subjects were female (91.9%). Subjects consisted of 23 (62.2%) limited SSc and 14 (37.8%) diffuse SSc. Six subjects (16.2%) were DMARD naïve. We found median (range) P1NP serum was 43.85 (9.81-127.90) ng/dL, while the median of MRSS was 14 (3-36). There is a moderate correlation between MRSS and P1NP serum (r=0.443, p=0.003)
Conclusion: There was a significant correlation between mRSS and P1NP serum in systemic sclerosis patient at Dr. Hasan Sadikin Hospital Bandung.

Keywords: systemic sclerosis, P1NP, modified rodnan skin score

Article Details

How to Cite
Vincent, V., Dewi, S., & Wachjudi, R. G. (2017). Correlation Between Serum Procollagen Type 1 N-Terminal Propeptide Level With Modified Rodnan Skin Score In Systemic Sclerosis Patients. Indonesian Journal of Rheumatology, 9(2).


  1. Mayes M, Assasi S. Classification and Epidemiology of scleroderma. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editor. Rheumatology (Oxford). Edisi ke-6. Philadelphia: Elsevier; 2015: p.1153-7.
  2. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009;48 (Suppl 3):3-7.
  3. Haustein UF. Systemic Sclerosis - An Update. Lab Med. 2011;42(9):562-72.
  4. Walker JG, Fritzler MJ. Systemic Sclerosis. Dalam: Shoenfeld Y, R. C, Gershwin ME, editor. Diagnostic Criteria in Autoimune Diseases. New York: Humana press; 2008:31.
  5. Mulasimadhi K, Wachjudi RG, Rahmadi AR. Perubahan Pola Penyakit Pasien Di Klinik Reumatologi RSUP Dr. Hasan Sadikin Sebelum dan Sesudah Era Jaminan Kesehatan Nasional [Skripsi]. Divisi Rumatologi, Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Padjajaran;2015.
  6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-4.
  7. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700-6.
  8. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017-26.
  9. Czirjak L, Foeldvari I, Muller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxford). 2008;47 (Suppl 5):44-5.
  10. Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE.The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis. 2007;66(7):966-9.
  11. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, lacebocontrolled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323-33.
  12. Moinzadeh P, Denton C, Abraham D, Ong V, Hunzelmann N, Eckes B, et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol. 2012;26(3):267-76.
  13. Scheja A, Wildt M, Wollheim FA, Ã…kesson A, Saxne T. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford). 2000;39(10):1110-3.
  14. Denton C, Black C, Korn J, De Crombrugghe B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. The Lancet. 1996;347(9013):1453-8
  15. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am. 2005;34(4):1015-30.
  16. Lee J, Vasikaran S. Current Recommendations for Laboratory Testing andUse of Bone Turnover Markers in Management of Osteoporosis. Ann Lab Med. 2012; 32(2): 105-12
  17. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9.
  18. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, et al. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat.2013;137(2):631-6
  19. Kucukalic-Selimovic E, Valjevac A, Hadzovic-Dzuvo A. The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. Bosn J Basic Med Sci. 2013;13(4):259-65
  20. Cavalier E, Lukas P, Carlisi A, Gadisseur R, Delanaye P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta. 2013;425:117-8
  21. Varga J. Systemic sclerosis: epidemiology, pathology and pathogenesis. Primer on rheumatic diseases 13th ed Atlanta: Springer. 2008:351-8.
  22. Denton C, Black C, Korn J, De Crombrugghe B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. The Lancet. 1996;347(9013):1453-8.
  23. Arnett FC, Gourh P, Shete S, Ahn CW, Honey R, Agarwal SK, et al. Major Histocompatibility Complex (MHC) class II alleles, haplotypes, and epitopes which confer susceptibility or protection in the fibrosing autoimmune disease systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010;69(5):822-7. doi: 10.1136/ard.2009.111906
  24. He D, Wang J, Yi L, Guo X, Guo S, Guo G, et al. Association of the HLA-DRB1 with Scleroderma in Chinese Population. PLoS One. 2014 ;9(9): e106939.
  25. Pauling JD, McHugh N. The Clinical Aspects of Autoantibodies. In Scleroderma From Pathogenesis to Comprehensive Management. Varga J, Denton CP, Wigley FM, ed. New York: Springer; 2012: p.209-21.
  26. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360(19): 1989-2003.
  27. Ling ALH, Gee TG, Giap LW, Cheng NS, Santosa A, Chan G, et al. Disease Characteristics of the Singapore Systemic Sclerosis Cohort. Proceedings of Singapore Healthcare. 2013;22(1):8-14.
  28. Mayes MD. Systemic sclerosis. In Primer on the rheumatic diseases, 13thed. Klippel JH, Stone JH, Crofford LeJ, White PH, ed. New York: Springer;2008;343-62.
  29. Low A, Gee TG, Giap LW, Cheng NS, Santosa A, Chan G, et al. Disease Characteristics of the Singapore Systemic Sclerosis Cohort. Proceedings of Singapore Healthcare. 2013;22(1):8-14.
  30. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70(6):1104-7.
  31. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford). 2010;49(7):1336-45.
  32. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of Modified Rodnan Skin Score in Systemic Sclerosis Clinical Trials: Analysis of 3 Large Multicenter, Randomized Clinical Trials. Arthritis Rheum. 2009;60(8):2490-8.
  33. Varga J, Denton CP, Wigley FM. Scleroderma: From Pathogenesis to Comprehensive Management [ebook]. New York: Springer;2012.
  34. Minier T, Nagy Z, Balint Z, Farkas H, Radics J, Kumanovics G, et al. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford). 2010;49(6):1133-45.
  35. Varga J. Systemic Sclerosis : Epidemiology, pathology, and Pathogenesis.In Primer on The Rheumatic Disease, 13th edition. Klippel JH, Stone JH,Crofford LJ, White PH, editor. New York: Springer; 2008: p.351-8.
  36. Beyer C, distler O, distler JHW. Biomarker of Fibrosis. In Scleroderma From Pathogenesis to Comprehensive Management. Varga J, Denton CP, Wigley FM, editor. London: Springer; 2012: p.283-9.
  37. Minier T. Assesment of Disease Activity and Evaluation of Clinical Parameters and Biomarkers in Systemic Sclerosis. University of Pecs; 2011.
  38. Ponticos M, Papaioannou I, Xu S, Holmes AM, Khan K, Denton CP, et al. Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheumatol. 2015; 67 (1): 243-53